Rangeley Capital’s Spero Therapeutics SPRO Stock Holding History

Rangeley Capital’s Portfolio SPRO Stock Details SPRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-30,000	Closed	-$56.4K	–	156
2025 Q3	$56.4K	Buy	+30,000	New	+$66K	0.05%	117

Other funds holding SPRO

GSK plc London $599M AUM

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Rangeley Capital's SPRO Position: Q4 2025 in Review

Rangeley Capital sold out of Spero Therapeutics (SPRO) in Q4 2025, closing a stake of 30,000 shares — an estimated $56.4K sold.

Rangeley Capital first reported a position in SPRO in Q3 2025 and held it in 1 quarter. The position peaked at $56.4K in Q3 2025. 56 funds tracked by Wall St. Rank hold SPRO as of Q4 2025.

Rangeley Capital reported no remaining Spero Therapeutics position as of Q4 2025 after selling out during the quarter.
Rangeley Capital sold 30,000 Spero Therapeutics shares in Q4 2025, an estimated $56.4K.
Rangeley Capital first reported a position in Spero Therapeutics in Q3 2025 and held it in 1 quarter.
Rangeley Capital's Spero Therapeutics position peaked at $56.4K in Q3 2025.
56 funds tracked by Wall St. Rank held Spero Therapeutics as of Q4 2025.

Based on Rangeley Capital's 13F filing for Q4 2025, filed 17 Feb 2026.